MA45843A - Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) - Google Patents
Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)Info
- Publication number
- MA45843A MA45843A MA045843A MA45843A MA45843A MA 45843 A MA45843 A MA 45843A MA 045843 A MA045843 A MA 045843A MA 45843 A MA45843 A MA 45843A MA 45843 A MA45843 A MA 45843A
- Authority
- MA
- Morocco
- Prior art keywords
- ghrelin
- goat
- acyl transferase
- transferase inhibitors
- derivatives used
- Prior art date
Links
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title abstract 3
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title abstract 2
- 239000002404 acyltransferase inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical class C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000283707 Capra Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés de formule générale (i) dans lesquels les groupes r1, r2 et n sont tels que définis dans la revendication 1, qui ont des propriétés pharmacologiques valorisables, en particulier, qui se lient au ghréline o-acyl transférase (chèvre) et modulent son activité. Ces composés conviennent pour traiter et prévenir des maladies pouvant être influencées par ce récepteur, telles que des maladies métaboliques, en particulier l'obésité
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16183047 | 2016-08-05 | ||
| PCT/EP2017/069274 WO2018024653A1 (fr) | 2016-08-05 | 2017-07-31 | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45843A true MA45843A (fr) | 2019-06-12 |
| MA45843B1 MA45843B1 (fr) | 2021-06-30 |
Family
ID=56609762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45843A MA45843B1 (fr) | 2016-08-05 | 2017-07-31 | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9994591B2 (fr) |
| EP (1) | EP3494120B1 (fr) |
| JP (1) | JP6651054B2 (fr) |
| KR (1) | KR102496075B1 (fr) |
| CN (1) | CN109843891B (fr) |
| AR (1) | AR109296A1 (fr) |
| AU (1) | AU2017307033B2 (fr) |
| CL (1) | CL2019000274A1 (fr) |
| CO (1) | CO2019000601A2 (fr) |
| CY (1) | CY1124381T1 (fr) |
| DK (1) | DK3494120T3 (fr) |
| EA (1) | EA037277B1 (fr) |
| ES (1) | ES2874587T3 (fr) |
| HR (1) | HRP20210908T1 (fr) |
| HU (1) | HUE054928T2 (fr) |
| IL (1) | IL264506B (fr) |
| LT (1) | LT3494120T (fr) |
| MA (1) | MA45843B1 (fr) |
| MX (1) | MX384847B (fr) |
| MY (1) | MY197064A (fr) |
| PE (1) | PE20190414A1 (fr) |
| PH (1) | PH12019500254A1 (fr) |
| PL (1) | PL3494120T3 (fr) |
| PT (1) | PT3494120T (fr) |
| RS (1) | RS61937B1 (fr) |
| SA (1) | SA519401039B1 (fr) |
| SG (1) | SG11201811804QA (fr) |
| SI (1) | SI3494120T1 (fr) |
| TW (1) | TWI749042B (fr) |
| UA (1) | UA124267C2 (fr) |
| WO (1) | WO2018024653A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| AU2019215707A1 (en) * | 2018-02-02 | 2020-07-09 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors |
| EP3746449B1 (fr) * | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat) |
| WO2019149659A1 (fr) * | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021233882A1 (fr) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
| CN115916789B (zh) * | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| CN112014340A (zh) * | 2020-09-01 | 2020-12-01 | 广西玮美生物科技有限公司 | 非人灵长类动物胃饥饿素的检测方法 |
| CN118652261B (zh) * | 2024-05-29 | 2025-02-07 | 南京理工大学 | 一种耐热荧光活性含能化合物及其合成方法 |
| US20260083736A1 (en) | 2024-09-24 | 2026-03-26 | Boehringer Ingelheim International Gmbh | Ghrelin o-acyl transferase (goat) inhibitors for use in the treatment of substance use disorder in patients with high impulsivity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| WO2008071646A1 (fr) | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | Nouveaux dérivés pyridazines à activité antagoniste du récepteur mch et médicaments comprenant ces composés |
| CA2677932A1 (fr) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Co-agonistes des recepteurs du glucagon/glp-1 |
| EP2158214B1 (fr) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Analogues du glucagon |
| EP2370462B1 (fr) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Analogues du glucagon |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CN102282167B (zh) | 2008-12-15 | 2014-08-13 | 西兰制药公司 | 胰高血糖素类似物 |
| ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| IN2014CN04401A (fr) | 2011-12-23 | 2015-09-04 | Zealand Pharma As | |
| US9238639B2 (en) * | 2012-02-24 | 2016-01-19 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (fr) * | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Petits inhibiteurs lipopeptidomimétiques de la ghréline o-acyl transférase |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AU2019215707A1 (en) * | 2018-02-02 | 2020-07-09 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors |
| EP3746449B1 (fr) * | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat) |
| WO2019149659A1 (fr) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
-
2017
- 2017-07-31 SG SG11201811804QA patent/SG11201811804QA/en unknown
- 2017-07-31 LT LTEP17743064.2T patent/LT3494120T/lt unknown
- 2017-07-31 DK DK17743064.2T patent/DK3494120T3/da active
- 2017-07-31 SI SI201730770T patent/SI3494120T1/sl unknown
- 2017-07-31 US US15/664,119 patent/US9994591B2/en active Active
- 2017-07-31 EP EP17743064.2A patent/EP3494120B1/fr active Active
- 2017-07-31 RS RS20210702A patent/RS61937B1/sr unknown
- 2017-07-31 HR HRP20210908TT patent/HRP20210908T1/hr unknown
- 2017-07-31 MX MX2019001427A patent/MX384847B/es unknown
- 2017-07-31 WO PCT/EP2017/069274 patent/WO2018024653A1/fr not_active Ceased
- 2017-07-31 MY MYPI2018002719A patent/MY197064A/en unknown
- 2017-07-31 ES ES17743064T patent/ES2874587T3/es active Active
- 2017-07-31 KR KR1020197006448A patent/KR102496075B1/ko active Active
- 2017-07-31 HU HUE17743064A patent/HUE054928T2/hu unknown
- 2017-07-31 JP JP2019506164A patent/JP6651054B2/ja active Active
- 2017-07-31 PT PT177430642T patent/PT3494120T/pt unknown
- 2017-07-31 CN CN201780047100.1A patent/CN109843891B/zh active Active
- 2017-07-31 MA MA45843A patent/MA45843B1/fr unknown
- 2017-07-31 UA UAA201901840A patent/UA124267C2/uk unknown
- 2017-07-31 PE PE2019000271A patent/PE20190414A1/es unknown
- 2017-07-31 AU AU2017307033A patent/AU2017307033B2/en active Active
- 2017-07-31 EA EA201990418A patent/EA037277B1/ru not_active IP Right Cessation
- 2017-07-31 PL PL17743064T patent/PL3494120T3/pl unknown
- 2017-08-04 TW TW106126319A patent/TWI749042B/zh active
- 2017-08-04 AR ARP170102213A patent/AR109296A1/es active IP Right Grant
-
2018
- 2018-05-09 US US15/974,882 patent/US10308667B2/en not_active Ceased
-
2019
- 2019-01-22 CO CONC2019/0000601A patent/CO2019000601A2/es unknown
- 2019-01-28 IL IL264506A patent/IL264506B/en active IP Right Grant
- 2019-02-01 CL CL2019000274A patent/CL2019000274A1/es unknown
- 2019-02-05 SA SA519401039A patent/SA519401039B1/ar unknown
- 2019-02-06 PH PH12019500254A patent/PH12019500254A1/en unknown
-
2020
- 2020-10-14 US US17/069,940 patent/USRE49446E1/en active Active
-
2021
- 2021-06-14 CY CY20211100525T patent/CY1124381T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45843B1 (fr) | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) | |
| EA200801934A1 (ru) | 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2 | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| MA20150065A1 (fr) | Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40 | |
| EA201000331A1 (ru) | 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны | |
| EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
| MA45153B1 (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA32654B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| MA50398B1 (fr) | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma | |
| MA38170A1 (fr) | Nouveaux acides indanyloxydihydrobenzofuranylacétiques | |
| EA200700617A1 (ru) | Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| MA40993B1 (fr) | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 | |
| PH12020551170A1 (en) | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| CR20200331A (es) | Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat) | |
| SA520412488B1 (ar) | مركبات لعلاج اضطرابات معتمدة على كيناز | |
| EA201190004A1 (ru) | Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3 | |
| EA201000675A1 (ru) | Производные хромана как модуляторы trpv3 | |
| EA201190086A1 (ru) | Сочлененные производные имидазола в качестве антагониста trpv3 | |
| MA39253B1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr |